Genzyme Corporation (NASDAQ:GENZ) decreased 0.48% to close at $71.01. GENZ traded 2.40 million shares for the day and its 52 weeks range remained $45.39 - $73.23. Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. It serves physicians, hospitals, treatment centers, other providers of medication to patients, retail pharmacies, and government agencies through distributors. The company was founded in 1981 and is based in Cambridge, Massachusetts.

PDL BioPharma Inc. (NASDAQ:PDLI) decreased 1.63% to close at $4.84. PDLI traded 2.37 million shares for the day and its earning per share remained $0.85. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

AVANIR Pharmaceuticals (NASDAQ:AVNR) decreased 1.40% to close at $4.23. AVNR traded 2.34 million shares for the day and its 52 weeks range remained $1.31 - $5.80. AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. The company also offers Abreva, an over-the-counter product for the treatment of cold sores. AVANIR Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Genzyme Corporation (NASDAQ:GENZ) decreased 0.08% to close at $72.34. GENZ traded 3.10 million shares for the day and its 52 weeks range remained $45.39 - $73.23. Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. The company’s Genetic Diseases segment manufactures and distributes Cerezyme for the treatment of Gaucher disease; Fabrazyme for the treatment of Fabry disease.

VIVUS, Inc. (NASDAQ:VVUS) increased 0.54% to close at $10.64. VVUS traded 2.99 million shares for the day and its 52 weeks range remained $4.69 - $13.68. VIVUS, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for underserved markets in the United States. It offers MUSE, a minimally invasive therapy for erectile dysfunction. The company’s investigational product pipeline includes Qnexa that has completed Phase 3 clinical trials for obesity, and Phase 2 clinical trials for diabetes and obstructive sleep apnea.

Dendreon Corporation (NASDAQ:DNDN) decreased 1.68% to close at $37.52. DNDN traded 2.90 million shares for the day and its 52 weeks range remained $25.78 - $57.67. Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy that has completed three Phase III trials for the treatment of metastatic.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

PTS, Inc. (OTC.BB:PTSH) announced that through its ThinLine division has signed a 3-year Voice Over Internet Protocol (VOIP) contract with MC Universal Art.

MC Universal Art has been designing and installing quality framed art for over 30 years. They are a leading provider of wholesale and retail art frames, fine art prints, signed limited additions, as well as providing interior design consulting services. MC Universal Art works with leading interior designers, architects, and office furniture dealers - they help their wholesale clients achieve an environment that drives the image and identity they want to project for customers.

MC Universal Art is expanding its office and manufacturing infrastructure and required a scalable communications system that can handle their growth without effecting customer service. They also had a need to insure that their IT architecture would not be impacted with their communication upgrade.

Following several queries from the investment community, PTSH explains the relationship with ThinLine and addresses its “70% ownership”. Raj Kalra, CEO of PTSH explains, “PTSH purchased my 70% ownership of ThinLine in a Share Exchange Agreement last week. In exchange of my 70% ownership I received restricted shares of PTSH stock. ThinLine has two owners, PTSH (70%) and a second party (30%). ThinLine is a subsidiary of PTSH, owning 70% therefore shall receive 70% of the profits. In respect to why the deal won’t close until December 31, 2010 is due to two factors: 1) ThinLine has approx 70 days to complete SEC audits and; 2) PTSH has its year end 12/31/10, and it makes for easier accounting. For all intensive purposes it is business as usual for PTSH and ThinLine since the merger.

*******************************************************

Eline Entertainment Group, Inc. (PINK SHEETS:EEGI) has completed their merger with Vu365.

Vu365 has been looking to enter the US market for quite some time, and this merger is the perfect opportunity. According to sources, Vu365 offers revenues in the $2 million USD range, with profits of $500,000 USD.

Vu365 is a popular China-based video game designing company. Founded in 2005, the group designs online and casual video games including strategic web games, cyber games and 3D large scale competitive games and has several products in development.

EEGI is happy to have Vu365 on their team and feels that they are a nice complement to their existing subsidiary, Let the Good Times Roll.

*******************************************************

Genzyme Corp. (NASDAQ:GENZ) recently has responded to a letter sent by Sanofi-Aventis (NYSE:SNY) relating to its unsolicited tender offer.

GENZ’s response reiterated the unanimous view of its board of directors that the $69-per-share offer price is not an appropriate starting point for discussions because it dramatically undervalues the company.

*******************************************************

Ventas, Inc. (NYSE:VTR) recently has priced a public offering of $400 million aggregate principal amount of 3.125% Senior Notes due 2015 (the “notes”) at 99.528% of principal amount.

The notes are being issued by VTR’s operating partnership, Ventas Realty, Limited Partnership, and a wholly owned subsidiary, Ventas Capital Corporation (collectively, the “Issuers”), and will be guaranteed, on a senior unsecured basis, by the Company.

VTR expects to use the net proceeds from the offering to repay indebtedness outstanding under its unsecured revolving credit facilities and for working capital and other general corporate purposes, including to fund future acquisitions and investments, if any. Completion of the offering is subject to customary closing conditions. The sale of the notes is expected to close on November 16, 2010.

*******************************************************

Ambac Financial Group, Inc. (NYSE:ABK) recently has filed for a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code (“Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of New York (“Bankruptcy Court”).

ABK will continue to operate in the ordinary course of business as “debtor-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court.

****************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for PTS Inc.(PTSH.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Eline Entertainment Group, Inc. (EEGI.PK)

Crown Equity Holdings Inc. (OTCBB:CRWE) is pleased to report its financial results for the nine month period ending September 30, 2010. Revenue for the nine months totaled $1,073,383 compared to $418,959 during 2009. The Company incurred an operating loss of $54,527 for the nine months ending September 30, 2010 compared to an operating loss of $36,923 during the same period in 2009. Net loss of $343,049 for the nine months ending September 30, 2010 compared to a net loss of $29,379 for the same period in 2009. The net loss in 2010 was attributed mostly to an unrealized loss of $307,544 on securities held by the Company.

“Our continued progress in operations including an operating profit of $7,251 during the last quarter shows a continued growth in our business,” commented Kenneth Bosket, President and CEO of Crown Equity Holdings Inc. “Not only do our financial results show strong growth during this year but our continued investment in infrastructure will support our future growth,” stated Bosket.

Crown Equity Holdings Inc. is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients.

********************************************************

PTS, Inc. (OTC.BB:PTSH) announced that Raj Kalra has been named Chairman and Chief Executive Officer. Mr. Kalra replaces Teresa Rubio who has served as Chairman and Marc Pintar who has served as PTSH Interim Chief Executive Officer. In addition to his role as CEO, Mr. Kalra will serve on PTSH’s Board of Directors.

“I’m very pleased to be named the CEO of PTSH,” said Raj Kalra. “I am working very hard to bring value to our shareholders. My first order of business is to announce that PTSH, via ThinLine, has been granted a contract to develop and manage the modifications to a certain proprietary cloud computer software solution that ThinLine created based on the client’s requirements for an online inventory management system for contracts that they manage for cable operators nationally.” Raj Kalra continued, “This system tracks the sales process and contract maintenance between the cable operator and the property owner/investment company. It also tracks revenue sharing that is owed to the property based on right-of-entry agreements or tracking of bulk cable/internet agreements for the units of the property. This is a very meaningful contract for PTSH and shareholders will be advised of any additional developments as they unfold.”

********************************************************

Sanofi-aventis (NYSE:SNY) announced recently that it has sent a letter to Genzyme Corporation (NASDAQ:GENZ) requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme’s Schedule 14D-9.

Sanofi-Aventis, a healthcare company, engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone.

Genzyme Corporation operates as a biotechnology company worldwide.

********************************************************

Del Monte Foods Company (NYSE:DLM) recently announced that its Board of Directors has declared a cash dividend on its common stock of $0.09 per share. The dividend was payable on November 4, 2010 to stockholders of record as of the close of business on October 21, 2010.

****************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for PTS Inc.(PTSH.OB)

MusclePharm® Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, disclosed MuscleGel achieves NSF certification. In addition, MusclePharm’s Recon and Assault nutritional products will be NSF certified within the coming months.

MusclePharm products are currently available in 1,200 of the top General Nutrition Centers (GNC) in the United States, as well as Vitamin Shop. MusclePharm’s award-winning products — Assault®, Battle Fuel®, Bullet Proof®, Combat Powder®, Recon® and Shred Matrix®—are also available online at gnc.com, bodybuilding.com, amazon.com and many other locations.

MusclePharm’s top management has extensive experience in the sports world and has harnessed this drive and focus into building a business to benefit its customers and help Fuel The Athlete Inside™. Headquartered in Aurora, Colorado, MusclePharm is a fast-growing developer and manufacturer of safe, scientifically approved, nutritional supplements that are free of banned substances and tested by athletes.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Skyworks Solutions, Inc. (NasdaqGS: SWKS), an innovator of high reliability analog and mixed signal semiconductors enabling a broad range of end markets, remarked that Skyworks Solutions has launched several new complementary metal-oxide semiconductor (CMOS) switch matrix devices for the direct broadcast satellite (DBS) and cable television markets. Skyworks Solutions’ newest solutions eliminate the need for external components by integrating critical functionality directly on the CMOS die, providing customers with significant cost savings and reduced printed circuit board (PCB) space requirements.

Skyworks Solutions, Inc., together with its subsidiaries, offers analog and mixed signal semiconductors worldwide. Skyworks Solutions provides power amplifiers and front-end solutions for cellular devices from entry level to multimedia platforms and smart phones.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

At the Academy of Managed Care Pharmacy (AMCP) 2010 Educational Conference taking place in St. Louis this week, Express Scripts (Nasdaq:ESRX) will present research findings that spotlight new opportunities for driving down healthcare costs and providing increased value for health plan sponsors and patients. The new research identifies a specific set of opportunities for health plan sponsors and their members to reach healthier outcomes and lower costs.

Express Scripts, Inc. provides a range of pharmacy benefit management (PBM) services in North America. Express Scripts’ PBM services include retail network pharmacy management and retail drug card programs; home delivery pharmacy services; specialty pharmacy services; patient care contact centers; benefit plan design and consultation; drug formulary management; compliance and therapy management programs.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Genzyme Corp. (NasdaqGS: GENZ) declared that details for three Analyst and Investor events that are planned for the month of October. The details can be found on the investor events section of www.genzyme.com.

Genzyme Corporation operates as a biotechnology company worldwide. Genzyme focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. Genzyme’s Genetic Diseases segment manufactures and distributes Cerezyme for the treatment of Gaucher disease; Fabrazyme for the treatment of Fabry disease; Myozyme for the treatment of Pompe disease; Aldurazyme for the treatment of Mucopolysaccharidosis I; and Elaprase for the treatment of Mucopolysaccharidosis II.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).